Navigation Links
arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work
Date:9/10/2009

echnology, information technology and other high technology opportunities that offer venture capital returns.

About Thuja Capital Healthcare Funds - http://www.thujacapital.com

The Thuja Capital Healthcare Fund and Thuja Capital Healthcare Seed Fund are venture capital funds structured to invest in life sciences innovations with a focus on therapeutics, diagnostics and medical devices. Whereby the prime focus of the Seed Fund is on privately held early-stage life sciences companies located in the Netherlands. The Thuja Capital Healthcare Seed Fund and the Thuja Capital Healthcare Fund are managed by Thuja Capital. In addition, Thuja Capital is the exclusive manager of AlpInvest Partners' portfolio of early stage life sciences companies. Thuja Capital's team has a long-standing track record in successful life science investments. Apart from equity investments, Thuja Capital aims to actively help their portfolio companies to strengthen and grow their businesses.

    For further information, please contact:

    Citigate Dewe Rogerson
    David Dible, Mark Swallow
    T: +44-207-282-2949 / 2948
    E: David.Dible@citigatedr.co.uk

    arGEN-X
    Tim Van Hauwermeiren, MSc, eMBA
    Chief Executive Officer
    T: +31-6-122-85-257
    E: tim.vh@arGEN-X.com


'/>"/>
SOURCE arGEN-X
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), a ... therapies in new orphan drug indications, today announced that ... added as a clinical trial site for the ongoing, ... refractory glioblastoma multiforme (GBM), the most common and deadly ...
(Date:4/16/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... personalized immune therapies for cancer, announced today that ... Immunotherapy Index (LCINDX), a professional index recently established ... within the biotechnology space.  The ... in the immunotherapy space, including 6 big pharma ...
(Date:4/16/2015)... 16, 2015 Modality Solutions, a ... for highly regulated industries, is pleased to announce ... monthly columnist for Cold Chain IQ - Temperature ... His column titled, Global Cold Chain Connections, is ... today’s life sciences, pharmaceutical and healthcare supply chains. ...
(Date:4/15/2015)... 16, 2015 Immunocore Limited, ... to treat cancer and other diseases, and MedImmune, ... AstraZeneca, today announced that they have entered into ... of the agreement, Immunocore will conduct a Phase ... MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore,s ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... , Nearly 200 Quantitative Immunoassays for Discovery and ... AUSTIN, Texas, June 17 Rules-Based Medicine, Incorporated ... today announced the availability of the most comprehensive ... safety, efficacy and efficiency in drug and diagnostic ...
... This ... carbon emissions, with the ultimate goal of becoming carbon neutral. This resolution also committed ... allowing airports to make their commitment a reality. , ... Manchester, UK (PRWEB) June 17, 2009 -- This ...
... Systems, a privately-held company, announced today that they ... Lyse Different Cell Types". This method, originally applied ... DNA from a mixed forensic sample, has broad ... processes for analysis and identification. Combined with the ...
Cached Biology Technology:Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3European Airports Actively Engaging on Reducing CO2, Despite the Crisis 2European Airports Actively Engaging on Reducing CO2, Despite the Crisis 3MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... sperm whale and its large prey, the jumbo squid, ... reaching depths of 3,000 feet or more. Now, in ... the successful tagging of sperm whales and jumbo squid ... electronic tracking devices have been applied simultaneously to deep-diving ...
... a type of stem cells from the lungs of transplant ... reside in adult organs and are not derived from bone ... be able to help with the rejection of donated organs ... study by University of Michigan Health System researchers is significant ...
... January issue of the journal Cell Metabolism, published by Cell ... formation of a poorly understood type of muscle. Moreover, they ... fibers were able to run farther and at higher work ... lead to novel drugs designed to change the composition of ...
Cached Biology News:Tracking sperm whales and jumbo squid 2Tracking sperm whales and jumbo squid 3Tracking sperm whales and jumbo squid 4Tracking sperm whales and jumbo squid 5Tracking sperm whales and jumbo squid 6Type of stem cell found to reside in transplanted lungs 2Type of stem cell found to reside in transplanted lungs 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3